Descriptive Analysis of Dosing and Outcomes for Patients with Ibrutinib-Treated Relapsed or Refractory Chronic Lymphocytic Leukemia in a Canadian Centre

Abstract

More than half the study patients received ibrutinib therapy at a submaximal dose without evidence of increased frequency of toxicities or disease progression. The rate of ibrutinib discontinuation was lower in our cohort than has been reported in other settings. Submaximal ibrutinib dosing will have to be further systematically evaluated.